Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

13G Filing: Park West Asset Management and Eagle Pharmaceuticals Inc. (EGRX)

You can access the original SEC filing by clicking here.

Ownership Summary Table

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
Park West Asset Management 786,420 0 786,420 0 786,420 5.2%
Peter S. Park 786,420 0 786,420 0 786,420 5.2%
Peter S. Park
Peter S. Park
Park West Asset Management

Page 1 of 8 – SEC Filing

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

SCHEDULE 13G

 

 

Under the Securities Exchange Act of 1934

(Amendment No.  )*

 

 

EAGLE
PHARMACEUTICALS, inc.

(Name of Issuer)

Common
Stock, $0.001 par value per share

(Title of Class of Securities)

269796108

(CUSIP Number)

August
14, 2017

(Date of Event Which Requires Filing of this
Statement)

Check the appropriate box to designate the
rule pursuant to which this Schedule 13G is filed:

[   ] Rule 13d-1(b)

[X] Rule 13d-1(c)

[   ] Rule 13d-1(d)

* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this
form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter
the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be “filed”
for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities
of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

Follow Eagle Pharmaceuticals Inc. (NASDAQ:EGRX)
Trade (NASDAQ:EGRX) Now!

Page 2 of 8 – SEC Filing

CUSIP No.  269796108
(1) Names of Reporting Persons
Park West Asset Management LLC
(2) Check the Appropriate Box if a Member of a Group (a) [    ]
(b) [    ]
(3) SEC Use Only
(4) Citizenship or Place of Organization
Delaware
Number of Shares Beneficially Owned By Each Reporting Person With
(5) Sole Voting Power: 786,420*
(6) Shared Voting Power: 0  
(7) Sole Dispositive Power: 786,420*
(8) Shared Dispositive Power: 0  
   
(9) Aggregate Amount Beneficially Owned by Each Reporting Person
786,420*
(10) Check if the Aggregate Amount  in Row (9) Excludes Certain Shares (See Instructions):
[    ]
(11) Percent of Class Represented by Amount in Row (9)
5.2%
(12) Type of Reporting Person
IA

  *
Beneficial ownership percentage is based upon 15,169,241 shares of
common stock, $0.001 par value per share (“Common Stock”), of Eagle Pharmaceuticals, Inc., a Delaware corporation
(the “Company”), issued and outstanding as of August 2, 2017, based on information reported by the Company in its
Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 9, 2017. Park West Asset Management
LLC (“PWAM”) is the investment manager to Park West Investors Master Fund, Limited, a Cayman Islands exempted
company (“PWIMF”), and Park West Partners International, Limited, a Cayman Islands exempted company
(“PWPI” and, collectively with PWIMF, the “PW Funds”), and Peter S. Park (“Mr. Park” and,
collectively with PWAM, the “Reporting Persons”) is the sole member and manager of PWAM. As of August 14, 2017,
PWIMF held 697,739 shares of Common Stock and PWPI held 88,681 shares of Common Stock. As a result of the foregoing, for
purposes of Reg. Section 240.13d-3, the Reporting Persons may be deemed to beneficially own the 786,420 shares of Common
Stock held in the aggregate by the PW Funds, or approximately 5.2% of the shares of Common Stock deemed to be issued and
outstanding as of August 14, 2017.

Follow Eagle Pharmaceuticals Inc. (NASDAQ:EGRX)
Trade (NASDAQ:EGRX) Now!

Page 3 of 8 – SEC Filing

CUSIP No.  269796108
(1) Names of Reporting Persons
Peter S. Park
(2) Check the Appropriate Box if a Member of a Group (a) [    ]
(b) [    ]
(3) SEC Use Only
(4) Citizenship or Place of Organization
United States of America
Number of Shares Beneficially Owned By Each Reporting Person With
(5) Sole Voting Power: 786,420*
(6) Shared Voting Power: 0  
(7) Sole Dispositive Power: 786,420*
(8) Shared Dispositive Power: 0  
   
(9) Aggregate Amount Beneficially Owned by Each Reporting Person
786,420*
(10) Check if the Aggregate Amount  in Row (9) Excludes Certain Shares (See Instructions):
[    ]
(11) Percent of Class Represented by Amount in Row (9)
5.2%*
(12) Type of Reporting Person
IN

 * Beneficial
ownership percentage is based upon 15,169,241 shares of common stock,
$0.001 par value per share (“Common Stock”), of Eagle Pharmaceuticals, Inc., a Delaware corporation (the “Company”),
issued and outstanding as of August 2, 2017, based on information reported by the Company in its Quarterly Report on Form 10-Q
filed with the Securities and Exchange Commission on August 9, 2017. Park West Asset Management LLC (“PWAM”) is the
investment manager to Park West Investors Master Fund, Limited, a Cayman Islands exempted company (“PWIMF”), and Park
West Partners International, Limited, a Cayman Islands exempted company (“PWPI” and, collectively with PWIMF, the
“PW Funds”), and Peter S. Park (“Mr. Park” and, collectively with PWAM, the “Reporting Persons”)
is the sole member and manager of PWAM. As of August 14, 2017, PWIMF held 697,739 shares of Common Stock and PWPI held 88,681
shares of Common Stock. As a result of the foregoing, for purposes of Reg. Section 240.13d-3, the Reporting Persons may be deemed
to beneficially own the 786,420 shares of Common Stock held in the aggregate by the PW Funds, or approximately 5.2% of the shares
of Common Stock deemed to be issued and outstanding as of August 14, 2017.

Follow Eagle Pharmaceuticals Inc. (NASDAQ:EGRX)
Trade (NASDAQ:EGRX) Now!

Page 4 of 8 – SEC Filing


Item 1(a).  Name Of Issuer:  Eagle Pharmaceuticals, Inc. (the “Company”)
Item 1(b).  Address of Issuer’s Principal Executive Offices:

1880 Embarcadero Road

Palo Alto, CA 94303

Item 2(a).  Name of Person Filing:

This report on Schedule 13G (this “Schedule 13G”), is being jointly filed by (i) Park West Asset
Management LLC (“PWAM”), a Delaware limited liability company and the investment manager to (a) Park West Investors
Master Fund, Limited (“PWIMF”), a Cayman Islands exempted company that is the holder of 697,739 shares of common stock,
$0.001 par value per share (“Common Stock”), of the Company reported on this Schedule 13G, and (b) Park West Partners
International, Limited (“PWPI” and, collectively with PWIMF, the “PW Funds”), a Cayman Islands exempted
company that is the holder of 88,681 shares of Common Stock reported on this Schedule 13G; and (ii) Peter S. Park, as the sole
member and manager of PWAM (“Mr. Park” and, collectively with PWAM, the “Reporting Persons”).

The 786,420 shares of Common Stock held in the aggregate by the PW Funds, which constitute approximately 5.2%
of the shares of Common Stock deemed to be outstanding as of August 14, 2017, may be deemed to be beneficially owned (x) indirectly
by PWAM, as the investment adviser to PWIMF and PWPI, and (y) indirectly by Mr. Park, as the sole member and manager of PWAM.

Item 2(b).  Address of Principal Business Office or, if None, Residence:

The address for the Reporting Persons is: 900 Larkspur Landing Circle, Suite 165, Larkspur, California 94939.

Item 2(c).  Citizenship:

PWAM is organized under the laws of the State of Delaware. Mr. Park is a citizen of the United States.

Item 2(d).  Title of Class of Securities:
Common Stock, $0.001 par value per share.
Item 2(e).  CUSIP No.:
269796108

Follow Eagle Pharmaceuticals Inc. (NASDAQ:EGRX)
Trade (NASDAQ:EGRX) Now!

Page 5 of 8 – SEC Filing

Item 3.  If This Statement Is Filed Pursuant to Rules 13d-1(b) or 13d-2(b) or (c), Check Whether the Person Filing is a:
Not Applicable.
Item 4.  Ownership:
As reported in the cover pages to this report, the ownership information with respect to each of PWAM and Mr.
Park is as follows:

(a)     Amount Beneficially Owned: 786,420*
(b)    Percent of Class: 5.2%*
(c)     Number
of Shares as to which the person has:
(i)     Sole power to vote or to direct the vote: 786,420*
(ii)     Shared power to vote or to direct the vote: 0  
(iii)     Sole power to dispose or to direct the disposition of: 786,420*
(iv)     Shared power to dispose or to direct the disposition of: 0  

* This Schedule 13G is being jointly filed by (i) PWAM, a Delaware limited liability company and the investment
manager to (a) PWIMF, a Cayman Islands exempted company that is the holder of 697,739 shares of Common Stock, as reported on this
Schedule 13G, and (b) PWPI, a Cayman Islands exempted company that is the holder of 88,681 shares of Common Stock, as reported
on this Schedule 13G; and (ii) Mr. Park, as the sole member and manager of PWAM.

The 786,420 shares of Common Stock held in the aggregate by the PW Funds, which constitute approximately 5.2%
of the shares of Common Stock deemed to be outstanding as of August 14, 2017, may be deemed to be beneficially owned (x) indirectly
by PWAM, as the investment adviser to PWIMF and PWPI, and (y) indirectly by Mr. Park, as the sole member and manager of PWAM. The
foregoing beneficial ownership percentage is based upon 15,169,241 shares of Common Stock issued and outstanding as of August 2,
2017, based on information reported by the Company in its Quarterly Report on Form 10-Q filed with the Securities and Exchange
Commission on August 9, 2017.

Item 5.  Ownership of Five Percent or Less of a Class:
If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased
to be the beneficial owner of more than five percent of the class of securities, check the following: [   ]
Item 6.  Ownership of More Than Five Percent on Behalf of Another Person:
Not Applicable.
Item 7.  Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person:
Not Applicable.
Item 8.  Identification and Classification of Members of the Group:
Not Applicable.
Item 9.  Notice of Dissolution of Group:
Not Applicable.
Item 10.  Certification:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above
were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of
the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose
or effect.

Follow Eagle Pharmaceuticals Inc. (NASDAQ:EGRX)
Trade (NASDAQ:EGRX) Now!

Page 6 of 8 – SEC Filing

SIGNATURE

          After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth
in this statement is true, complete and correct.

August 24,
2017
PARK WEST ASSET MANAGEMENT LLC
By: /s/
Grace Jimenez
Name: Grace Jimenez
Title: Chief Financial Officer
/s/ Peter S. Park
Peter S. Park

 

Attention: Intentional misstatements or omissions
of fact constitute

Federal criminal violations (See 18 U.S.C.
1001)

 

Follow Eagle Pharmaceuticals Inc. (NASDAQ:EGRX)
Trade (NASDAQ:EGRX) Now!

Page 7 of 8 – SEC Filing

Exhibit Index

Exhibit

A.  Joint Filing Agreement, dated as of August 24, 2017, by and between Park West Asset Management LLC and Peter
S. Park.

Follow Eagle Pharmaceuticals Inc. (NASDAQ:EGRX)
Trade (NASDAQ:EGRX) Now!

Page 8 of 8 – SEC Filing

Exhibit A

 

 

JOINT FILING AGREEMENT

In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the persons named
below agree to the joint filing on behalf of them of a statement on Schedule 13G (including amendments thereto) with respect to
the shares of common stock, $0.001 par value per share, of Eagle Pharmaceuticals, Inc., a Delaware corporation, and further agree
that this Joint Filing Agreement be included as Exhibit A to such Schedule 13G. In evidence thereof, the undersigned hereby execute
this agreement this 24th day of August, 2017.

/s/ Peter S. Park
Peter S. Park
PARK WEST ASSET MANAGEMENT LLC
By: /s/
Grace Jimenez
Name: Grace Jimenez
Title: Chief Financial Officer

 

Follow Eagle Pharmaceuticals Inc. (NASDAQ:EGRX)
Trade (NASDAQ:EGRX) Now!